

### Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in this application.

#### Listing of Claims:

1-20. (Canceled).

21. (Currently amended) A pharmaceutical composition comprising R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(-) stereoisomer; a therapeutically effective amount of at least one other therapeutic agent; and a pharmaceutically acceptable carrier, wherein the other therapeutic agent is fluoxetine or the R or S isomer thereof, norcisapride or the (+) or (-) isomer thereof, ubidecarenone, dipyrámole, pilocarpine or a stereoisomer thereof, primidone or the R or S isomer thereof, or orphenadrine citrate.

22. (Canceled).

23. (Previously presented) The pharmaceutical composition of claim 21, wherein the R(+) ondansetron, or a pharmaceutically acceptable salt thereof, is greater than approximately 90% by weight of the total ondansetron.

24. (Previously presented) The composition of claim 21, comprising R(+) ondansetron hydrochloride.

25. (Previously presented) The composition of claim 21, wherein the amount of R(+) ondansetron, or a pharmaceutically acceptable salt thereof, ranges from about 0.001 mg to about 35 mg.

26. (Previously presented) The composition of claim 21, adapted for oral administration.

27. (Previously presented) The composition of claim 21, adapted for parenteral administration.

28. (Previously presented) The composition of claim 21, wherein the other therapeutic agent is fluoxetine or the R or S isomer thereof.

29. (Previously presented) The composition of claim 21, wherein the other therapeutic agent is norcisapride or the (+) or (-) isomer thereof.

30. (Previously presented) The composition of claim 21, wherein the other therapeutic agent is ubidecarenone.

31. (Previously presented) The composition of claim 21, wherein the other therapeutic agent is dipyrámole.

32. (Previously presented) The composition of claim 21, wherein the other therapeutic agent is pilocarpine or a stereoisomer thereof.

33. (Previously presented) The composition of claim 21, wherein the other therapeutic agent is primidone or the R or S isomer thereof.

34. (Previously presented) The composition of claim 21, wherein the other therapeutic agent is orphenadrine citrate.